Home Tags XMT-2056

Tag: XMT-2056

Mersana Therapeutics Confirms Clinical Hold on Phase 1 Study of XMT-2056

Clinical-stage biopharmaceutical company Mersana Therapeutics has confirmed that the Phase 1 trial of XMT-2056, an investigational immunosynthen STING-agonist ADC, has been placed on clinical hold by the U.S. Food and Drug Administration (FDA).

Mersana and GSK Sign Option Agreement for the Co-Development and Commercialization...

Mersana Therapeutics and GSK have confirmed that the companies have entered into a global collaboration that provides GSK an exclusive option to co-develop and...

X